What question did this study set out to answer?

This analysis explores the implications of the FDA's guidance on using Bayesian methodology in clinical trials.

June 10, 2026Significance

The FDA wants Bayesian trials, but who chooses the prior?

View Full Paper

Ask AI

Bookmark

This analysis explores the implications of the FDA's guidance on using Bayesian methodology in clinical trials.
Review of FDA draft guidance on Bayesian trials.
Discussion on prior distribution choices and their impact.
Highlights the role of prior distributions in Bayesian analyses.
Addresses questions on who determines these priors in clinical trials.

Implication

Randomized trials utilize Bayesian methods for drug approval, encouraging innovative approaches in research.

Abstract

Earlier this year, new draft guidance from the US Food and Drug Administration encouraged the use of Bayesian methodology in clinical trials for new drugs. Lu (Maggie) Qian addresses some of the questions arising from this development

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lu Qian (2026) studied this question.

synapsesocial.com/papers/6a2901536f82f25be989da22 https://doi.org/10.1093/jrssig/qmag038

View Full Paper

Ask AI

Bookmark

Implication

Randomized trials utilize Bayesian methods for drug approval, encouraging innovative approaches in research.

The FDA wants Bayesian trials, but who chooses the prior?

Key Points

Implication

Abstract

Discussion

Cite This Study

The FDA wants Bayesian trials, but who chooses the prior?

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading